As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.